慢性疼痛市場の評価：製品・疼痛タイプ・適応症・流通チャネル・地域別の機会および予測 (2017～2031年)

世界の慢性疼痛の市場規模は、2023年の858億2,000万米ドルから、2024年から2031年の予測期間中は6.28%のCAGRで推移し、2031年には1,396億5,000万米ドルの規模に成長すると予測されています。

慢性疼痛の市場は、慢性疼痛の有病率の増加、高齢者人口の増加、疼痛管理のための臨床開発の進行といった要因の影響を受けて拡大すると予測されています。慢性疼痛の有病率は複数の要因によって増加傾向にあり、市場成長の主な促進要因となっています。高齢化人口の増加、慢性疾患や疼痛を引き起こす健康状態の増加、癌患者の増加などが慢性疼痛有病率の上昇に寄与しており、慢性疼痛管理ソリューションの需要を高めています。

さらに、疼痛管理に関する臨床科学の進歩や開発が進んでいることも、新製品や先進的な製品を通じて市場の技術革新を促しています。現在、疼痛管理にはオピオイド、非ステロイド性抗炎症薬、抗うつ薬、局所麻酔薬などの薬剤クラスがあり、経口剤だけでなく局所投与剤もあります。これと並んで、患者向けの疼痛管理機器の技術革新も市場の成長を促しています。メーカーは常に革新的な製品の発売、臨床試験、特許申請、市場拡大のための市場戦術の活用を競っています。

慢性疼痛の蔓延

慢性疼痛は世界の臨床上での大きな関心事の一つです。腰痛、頚部痛、変形性関節症が慢性疼痛の中でもっとも一般的なものであり、世界の身体障害の大きな割合を占めています。慢性疼痛が増加している主な理由としては、高齢化、座りっぱなしのライフスタイル、肥満、怪我や外傷、癌の症例、職業に関連した理由などが挙げられます。従来の疼痛管理技術では、オピオイドや数種類のハーブを使用するのに対し、現代的な手法では、自然由来または合成化学物質や特殊な器具を使用して痛みを和らげます。

疼痛管理の臨床的発展

疼痛管理の分野には、心理学的介入、薬理学、侵襲的処置、非薬理学的アプローチ、非従来型療法など、幅広いアプローチがあります。疼痛管理に関するエビデンスに基づくガイドラインを確立し、健康格差のある患者を含むすべての患者が安全で効果的な疼痛管理療法を受けられるようにするため、NIH HEAL Initiativeは新たな臨床試験や既存のプログラムの拡大を支援しています。現在進行中の疼痛管理の臨床試験では、疼痛治療薬の医薬品開発プログラムの成果とパラメータが検討されています。個人の痛みの状態に対する包括的な治療には、身体的、感情的、社会的側面が含まれるべきと考えられています。

当レポートでは、世界の慢性疼痛の市場を調査し、市場の定義と概要、市場規模の推移・予測、各種区分・地域別の詳細分析、産業構造、市場成長への影響因子の分析、ケーススタディ、競合情勢、主要企業のプロファイルなどをまとめています。

目次

第1章 調査手法

第2章 プロジェクトの範囲と定義

第3章 エグゼクティブサマリー

第4章 世界の慢性疼痛市場の展望

• 市場規模・予測
• 製品別
  • 薬剤
  • デバイス
• 疼痛タイプ別
  • 神経因性疼痛
  • 関節炎性疼痛
  • 慢性腰痛
  • 癌性疼痛
  • 片頭痛
  • 線維筋痛症
  • その他
• 適応症別
  • 筋骨格系
  • 神経障害
  • 腫瘍
  • その他
• 流通チャネル別
  • 病院薬局
  • 小売薬局
  • オンライン薬局
• 地域別
  • 北米
  • 欧州
  • 南米
  • アジア太平洋
  • 中東・アフリカ
• 企業別の市場シェア

第5章 世界の慢性疼痛市場の展望：地域別

• 北米
• 欧州
• 南米
• アジア太平洋
• 中東・アフリカ

第6章 市場マッピング

• 製品別
• 疼痛タイプ別
• 適応症別
• 流通チャネル別
• 地域別

第7章 マクロ環境と産業構造

• 需給分析
• 輸出入分析
• バリューチェーン分析
• PESTEL分析
• ポーターのファイブフォース分析

第8章 市場力学

• 成長促進要因
• 成長阻害要因 (課題・抑制要因)

第9章 規制の枠組みとイノベーション

• 臨床試験
• 特許の情勢
• 規制当局の承認
• イノベーション/新興技術

第10章 主要企業の情勢

• 市場リーダー上位5社の競合マトリックス
• 市場リーダー上位5社の市場収益分析
• M&A・ジョイントベンチャー (該当する場合)
• SWOT分析（主要企業）

第11章 価格分析

第12章 ケーススタディ

第13章 主要企業の見通し

• Becton, Dickinson and Company
• Eli Lilly and Company
• Medtronic plc
• Johnson & Johnson Pte. Ltd.
• Novartis AG
• AstraZeneca PLC
• Bristol-Myers Squibb Company
• Sanofi S.A.
• Pfizer Inc.
• GlaxoSmithKline plc.

第14章 戦略的提言

第15章 当社について・免責事項

List of Tables

• Table 1. Pricing Analysis of Products from Key Players
• Table 2. Competition Matrix of Top 5 Market Leaders
• Table 3. Mergers & Acquisitions/ Joint Ventures (If Applicable)
• Table 4. About Us - Regions and Countries Where We Have Executed Client Projects

List of Figures

• Figure 1.Global Chronic Pain Market, By Value, In USD Billion, 2017-2031F
• Figure 2.Global Chronic Pain Market, By Volume, In Million Units, 2017-2031F
• Figure 3.Global Chronic Pain Market Share (%), By Product, 2017-2031F
• Figure 4.Global Chronic Pain Market Share (%), By Type of Pain, 2017-2031F
• Figure 5.Global Chronic Pain Market Share (%), By Indication, 2017-2031F
• Figure 6.Global Chronic Pain Market Share (%), By Distribution Channel, 2017-2031F
• Figure 7.Global Chronic Pain Market Share (%), By Region, 2017-2031F
• Figure 8.North America Chronic Pain Market, By Value, In USD Billion, 2017-2031F
• Figure 9.North America Chronic Pain Market, By Volume, In Million Units, 2017-2031F
• Figure 10.North America Chronic Pain Market Share (%), By Product, 2017-2031F
• Figure 11.North America Chronic Pain Market Share (%), By Type of Pain, 2017-2031F
• Figure 12.North America Chronic Pain Market Share (%), By Indication, 2017-2031F
• Figure 13.North America Chronic Pain Market Share (%), By Distribution Channel, 2017-2031F
• Figure 14.North America Chronic Pain Market Share (%), By Country, 2017-2031F
• Figure 15.United States Chronic Pain Market, By Value, In USD Billion, 2017-2031F
• Figure 16.United States Chronic Pain Market, By Volume, In Million Units, 2017-2031F
• Figure 17.United States Chronic Pain Market Share (%), By Product, 2017-2031F
• Figure 18.United States Chronic Pain Market Share (%), By Type of Pain, 2017-2031F
• Figure 19.United States Chronic Pain Market Share (%), By Indication, 2017-2031F
• Figure 20.United States Chronic Pain Market Share (%), By Distribution Channel, 2017-2031F
• Figure 21.Canada Chronic Pain Market, By Value, In USD Billion, 2017-2031F
• Figure 22.Canada Chronic Pain Market, By Volume, In Million Units, 2017-2031F
• Figure 23.Canada Chronic Pain Market Share (%), By Product, 2017-2031F
• Figure 24.Canada Chronic Pain Market Share (%), By Type of Pain, 2017-2031F
• Figure 25.Canada Chronic Pain Market Share (%), By Indication, 2017-2031F
• Figure 26.Canada Chronic Pain Market Share (%), By Distribution Channel, 2017-2031F
• Figure 27.Mexico Chronic Pain Market, By Value, In USD Billion, 2017-2031F
• Figure 28.Mexico Chronic Pain Market, By Volume, In Million Units, 2017-2031F
• Figure 29.Mexico Chronic Pain Market Share (%), By Product, 2017-2031F
• Figure 30.Mexico Chronic Pain Market Share (%), By Type of Pain, 2017-2031F
• Figure 31.Mexico Chronic Pain Market Share (%), By Indication, 2017-2031F
• Figure 32.Mexico Chronic Pain Market Share (%), By Distribution Channel, 2017-2031F
• Figure 33.Europe Chronic Pain Market, By Value, In USD Billion, 2017-2031F
• Figure 34.Europe Chronic Pain Market, By Volume, In Million Units, 2017-2031F
• Figure 35.Europe Chronic Pain Market Share (%), By Product, 2017-2031F
• Figure 36.Europe Chronic Pain Market Share (%), By Type of Pain, 2017-2031F
• Figure 37.Europe Chronic Pain Market Share (%), By Indication, 2017-2031F
• Figure 38.Europe Chronic Pain Market Share (%), By Distribution Channel, 2017-2031F
• Figure 39.Europe Chronic Pain Market Share (%), By Country, 2017-2031F
• Figure 40.Germany Chronic Pain Market, By Value, In USD Billion, 2017-2031F
• Figure 41.Germany Chronic Pain Market, By Volume, In Million Units, 2017-2031F
• Figure 42.Germany Chronic Pain Market Share (%), By Product, 2017-2031F
• Figure 43.Germany Chronic Pain Market Share (%), By Type of Pain, 2017-2031F
• Figure 44.Germany Chronic Pain Market Share (%), By Indication, 2017-2031F
• Figure 45.Germany Chronic Pain Market Share (%), By Distribution Channel, 2017-2031F
• Figure 46.France Chronic Pain Market, By Value, In USD Billion, 2017-2031F
• Figure 47.France Chronic Pain Market, By Volume, In Million Units, 2017-2031F
• Figure 48.France Chronic Pain Market Share (%), By Product, 2017-2031F
• Figure 49.France Chronic Pain Market Share (%), By Type of Pain, 2017-2031F
• Figure 50.France Chronic Pain Market Share (%), By Indication, 2017-2031F
• Figure 51.France Chronic Pain Market Share (%), By Distribution Channel, 2017-2031F
• Figure 52.Italy Chronic Pain Market, By Value, In USD Billion, 2017-2031F
• Figure 53.Italy Chronic Pain Market, By Volume, In Million Units, 2017-2031F
• Figure 54.Italy Chronic Pain Market Share (%), By Product, 2017-2031F
• Figure 55.Italy Chronic Pain Market Share (%), By Type of Pain, 2017-2031F
• Figure 56.Italy Chronic Pain Market Share (%), By Indication, 2017-2031F
• Figure 57.Italy Chronic Pain Market Share (%), By Distribution Channel, 2017-2031F
• Figure 58.United Kingdom Chronic Pain Market, By Value, In USD Billion, 2017-2031F
• Figure 59.United Kingdom Chronic Pain Market, By Volume, In Million Units, 2017-2031F
• Figure 60.United Kingdom Chronic Pain Market Share (%), By Product, 2017-2031F
• Figure 61.United Kingdom Chronic Pain Market Share (%), By Type of Pain, 2017-2031F
• Figure 62.United Kingdom Chronic Pain Market Share (%), By Indication, 2017-2031F
• Figure 63.United Kingdom Chronic Pain Market Share (%), By Distribution Channel, 2017-2031F
• Figure 64.Russia Chronic Pain Market, By Value, In USD Billion, 2017-2031F
• Figure 65.Russia Chronic Pain Market, By Volume, In Million Units, 2017-2031F
• Figure 66.Russia Chronic Pain Market Share (%), By Product, 2017-2031F
• Figure 67.Russia Chronic Pain Market Share (%), By Type of Pain, 2017-2031F
• Figure 68.Russia Chronic Pain Market Share (%), By Indication, 2017-2031F
• Figure 69.Russia Chronic Pain Market Share (%), By Distribution Channel, 2017-2031F
• Figure 70.Netherlands Chronic Pain Market, By Value, In USD Billion, 2017-2031F
• Figure 71.Netherlands Chronic Pain Market, By Volume, In Million Units, 2017-2031F
• Figure 72.Netherlands Chronic Pain Market Share (%), By Product, 2017-2031F
• Figure 73.Netherlands Chronic Pain Market Share (%), By Type of Pain, 2017-2031F
• Figure 74.Netherlands Chronic Pain Market Share (%), By Indication, 2017-2031F
• Figure 75.Netherlands Chronic Pain Market Share (%), By Distribution Channel, 2017-2031F
• Figure 76.Spain Chronic Pain Market, By Value, In USD Billion, 2017-2031F
• Figure 77.Spain Chronic Pain Market, By Volume, In Million Units, 2017-2031F
• Figure 78.Spain Chronic Pain Market Share (%), By Product, 2017-2031F
• Figure 79.Spain Chronic Pain Market Share (%), By Type of Pain, 2017-2031F
• Figure 80.Spain Chronic Pain Market Share (%), By Indication, 2017-2031F
• Figure 81.Spain Chronic Pain Market Share (%), By Distribution Channel, 2017-2031F
• Figure 82.Turkey Chronic Pain Market, By Value, In USD Billion, 2017-2031F
• Figure 83.Turkey Chronic Pain Market, By Volume, In Million Units, 2017-2031F
• Figure 84.Turkey Chronic Pain Market Share (%), By Product, 2017-2031F
• Figure 85.Turkey Chronic Pain Market Share (%), By Type of Pain, 2017-2031F
• Figure 86.Turkey Chronic Pain Market Share (%), By Indication, 2017-2031F
• Figure 87.Turkey Chronic Pain Market Share (%), By Distribution Channel, 2017-2031F
• Figure 88.Poland Chronic Pain Market, By Value, In USD Billion, 2017-2031F
• Figure 89.Poland Chronic Pain Market, By Volume, In Million Units, 2017-2031F
• Figure 90.Poland Chronic Pain Market Share (%), By Product, 2017-2031F
• Figure 91.Poland Chronic Pain Market Share (%), By Type of Pain, 2017-2031F
• Figure 92.Poland Chronic Pain Market Share (%), By Indication, 2017-2031F
• Figure 93.Poland Chronic Pain Market Share (%), By Distribution Channel, 2017-2031F
• Figure 94.South America Chronic Pain Market, By Value, In USD Billion, 2017-2031F
• Figure 95.South America Chronic Pain Market, By Volume, In Million Units, 2017-2031F
• Figure 96.South America Chronic Pain Market Share (%), By Product, 2017-2031F
• Figure 97.South America Chronic Pain Market Share (%), By Type of Pain, 2017-2031F
• Figure 98.South America Chronic Pain Market Share (%), By Indication, 2017-2031F
• Figure 99.South America Chronic Pain Market Share (%), By Distribution Channel, 2017-2031F
• Figure 100.South America Chronic Pain Market Share (%), By Country, 2017-2031F
• Figure 101.Brazil Chronic Pain Market, By Value, In USD Billion, 2017-2031F
• Figure 102.Brazil Chronic Pain Market, By Volume, In Million Units, 2017-2031F
• Figure 103.Brazil Chronic Pain Market Share (%), By Product, 2017-2031F
• Figure 104.Brazil Chronic Pain Market Share (%), By Type of Pain, 2017-2031F
• Figure 105.Brazil Chronic Pain Market Share (%), By Indication, 2017-2031F
• Figure 106.Brazil Chronic Pain Market Share (%), By Distribution Channel, 2017-2031F
• Figure 107.Argentina Chronic Pain Market, By Value, In USD Billion, 2017-2031F
• Figure 108.Argentina Chronic Pain Market, By Volume, In Million Units, 2017-2031F
• Figure 109.Argentina Chronic Pain Market Share (%), By Product, 2017-2031F
• Figure 110.Argentina Chronic Pain Market Share (%), By Type of Pain, 2017-2031F
• Figure 111.Argentina Chronic Pain Market Share (%), By Indication, 2017-2031F
• Figure 112.Argentina Chronic Pain Market Share (%), By Distribution Channel, 2017-2031F
• Figure 113.Asia-Pacific Chronic Pain Market, By Value, In USD Billion, 2017-2031F
• Figure 114.Asia-Pacific Chronic Pain Market, By Volume, In Million Units, 2017-2031F
• Figure 115.Asia-Pacific Chronic Pain Market Share (%), By Product, 2017-2031F
• Figure 116.Asia-Pacific Chronic Pain Market Share (%), By Type of Pain, 2017-2031F
• Figure 117.Asia-Pacific Chronic Pain Market Share (%), By Indication, 2017-2031F
• Figure 118.Asia-Pacific Chronic Pain Market Share (%), By Distribution Channel, 2017-2031F
• Figure 119.Asia-Pacific Chronic Pain Market Share (%), By Country, 2017-2031F
• Figure 120.India Chronic Pain Market, By Value, In USD Billion, 2017-2031F
• Figure 121.India Chronic Pain Market, By Volume, In Million Units, 2017-2031F
• Figure 122.India Chronic Pain Market Share (%), By Product, 2017-2031F
• Figure 123.India Chronic Pain Market Share (%), By Type of Pain, 2017-2031F
• Figure 124.India Chronic Pain Market Share (%), By Indication, 2017-2031F
• Figure 125.India Chronic Pain Market Share (%), By Distribution Channel, 2017-2031F
• Figure 126.China Chronic Pain Market, By Value, In USD Billion, 2017-2031F
• Figure 127.China Chronic Pain Market, By Volume, In Million Units, 2017-2031F
• Figure 128.China Chronic Pain Market Share (%), By Product, 2017-2031F
• Figure 129.China Chronic Pain Market Share (%), By Type of Pain, 2017-2031F
• Figure 130.China Chronic Pain Market Share (%), By Indication, 2017-2031F
• Figure 131.China Chronic Pain Market Share (%), By Distribution Channel, 2017-2031F
• Figure 132.Japan Chronic Pain Market, By Value, In USD Billion, 2017-2031F
• Figure 133.Japan Chronic Pain Market, By Volume, In Million Units, 2017-2031F
• Figure 134.Japan Chronic Pain Market Share (%), By Product, 2017-2031F
• Figure 135.Japan Chronic Pain Market Share (%), By Type of Pain, 2017-2031F
• Figure 136.Japan Chronic Pain Market Share (%), By Indication, 2017-2031F
• Figure 137.Japan Chronic Pain Market Share (%), By Distribution Channel, 2017-2031F
• Figure 138.Australia Chronic Pain Market, By Value, In USD Billion, 2017-2031F
• Figure 139.Australia Chronic Pain Market, By Volume, In Million Units, 2017-2031F
• Figure 140.Australia Chronic Pain Market Share (%), By Product, 2017-2031F
• Figure 141.Australia Chronic Pain Market Share (%), By Type of Pain, 2017-2031F
• Figure 142.Australia Chronic Pain Market Share (%), By Indication, 2017-2031F
• Figure 143.Australia Chronic Pain Market Share (%), By Distribution Channel, 2017-2031F
• Figure 144.Vietnam Chronic Pain Market, By Value, In USD Billion, 2017-2031F
• Figure 145.Vietnam Chronic Pain Market, By Volume, In Million Units, 2017-2031F
• Figure 146.Vietnam Chronic Pain Market Share (%), By Product, 2017-2031F
• Figure 147.Vietnam Chronic Pain Market Share (%), By Type of Pain, 2017-2031F
• Figure 148.Vietnam Chronic Pain Market Share (%), By Indication, 2017-2031F
• Figure 149.Vietnam Chronic Pain Market Share (%), By Distribution Channel, 2017-2031F
• Figure 150.South Korea Chronic Pain Market, By Value, In USD Billion, 2017-2031F
• Figure 151.South Korea Chronic Pain Market, By Volume, In Million Units, 2017-2031F
• Figure 152.South Korea Chronic Pain Market Share (%), By Product, 2017-2031F
• Figure 153.South Korea Chronic Pain Market Share (%), By Type of Pain, 2017-2031F
• Figure 154.South Korea Chronic Pain Market Share (%), By Indication, 2017-2031F
• Figure 155.South Korea Chronic Pain Market Share (%), By Distribution Channel, 2017-2031F
• Figure 156.Indonesia Chronic Pain Market, By Value, In USD Billion, 2017-2031F
• Figure 157.Indonesia Chronic Pain Market, By Volume, In Million Units, 2017-2031F
• Figure 158.Indonesia Chronic Pain Market Share (%), By Product, 2017-2031F
• Figure 159.Indonesia Chronic Pain Market Share (%), By Type of Pain, 2017-2031F
• Figure 160.Indonesia Chronic Pain Market Share (%), By Indication, 2017-2031F
• Figure 161.Indonesia Chronic Pain Market Share (%), By Distribution Channel, 2017-2031F
• Figure 162.Philippines Chronic Pain Market, By Value, In USD Billion, 2017-2031F
• Figure 163.Philippines Chronic Pain Market, By Volume, In Million Units, 2017-2031F
• Figure 164.Philippines Chronic Pain Market Share (%), By Product, 2017-2031F
• Figure 165.Philippines Chronic Pain Market Share (%), By Type of Pain, 2017-2031F
• Figure 166.Philippines Chronic Pain Market Share (%), By Indication, 2017-2031F
• Figure 167.Philippines Chronic Pain Market Share (%), By Distribution Channel, 2017-2031F
• Figure 168.Middle East & Africa Chronic Pain Market, By Value, In USD Billion, 2017-2031F
• Figure 169.Middle East & Africa Chronic Pain Market, By Volume, In Million Units, 2017-2031F
• Figure 170.Middle East & Africa Chronic Pain Market Share (%), By Product, 2017-2031F
• Figure 171.Middle East & Africa Chronic Pain Market Share (%), By Type of Pain, 2017-2031F
• Figure 172.Middle East & Africa Chronic Pain Market Share (%), By Indication, 2017-2031F
• Figure 173.Middle East & Africa Chronic Pain Market Share (%), By Distribution Channel, 2017-2031F
• Figure 174.Middle East & Africa Chronic Pain Market Share (%), By Country, 2017-2031F
• Figure 175.Saudi Arabia Chronic Pain Market, By Value, In USD Billion, 2017-2031F
• Figure 176.Saudi Arabia Chronic Pain Market, By Volume, In Million Units, 2017-2031F
• Figure 177.Saudi Arabia Chronic Pain Market Share (%), By Product, 2017-2031F
• Figure 178.Saudi Arabia Chronic Pain Market Share (%), By Type of Pain, 2017-2031F
• Figure 179.Saudi Arabia Chronic Pain Market Share (%), By Indication, 2017-2031F
• Figure 180.Saudi Arabia Chronic Pain Market Share (%), By Distribution Channel, 2017-2031F
• Figure 181.UAE Chronic Pain Market, By Value, In USD Billion, 2017-2031F
• Figure 182.UAE Chronic Pain Market, By Volume, In Million Units, 2017-2031F
• Figure 183.UAE Chronic Pain Market Share (%), By Product, 2017-2031F
• Figure 184.UAE Chronic Pain Market Share (%), By Type of Pain, 2017-2031F
• Figure 185.UAE Chronic Pain Market Share (%), By Indication, 2017-2031F
• Figure 186.UAE Chronic Pain Market Share (%), By Distribution Channel, 2017-2031F
• Figure 187.South Africa Chronic Pain Market, By Value, In USD Billion, 2017-2031F
• Figure 188.South Africa Chronic Pain Market, By Volume, In Million Units, 2017-2031F
• Figure 189.South Africa Chronic Pain Market Share (%), By Product, 2017-2031F
• Figure 190.South Africa Chronic Pain Market Share (%), By Type of Pain, 2017-2031F
• Figure 191.South Africa Chronic Pain Market Share (%), By Indication, 2017-2031F
• Figure 192.South Africa Chronic Pain Market Share (%), By Distribution Channel, 2017-2031F
• Figure 193.By Product Map-Market Size (USD Billion) & Growth Rate (%), 2023
• Figure 194.By Type of Pain Map-Market Size (USD Billion) & Growth Rate (%), 2023
• Figure 195.By Indication Map-Market Size (USD Billion) & Growth Rate (%), 2023
• Figure 196.By Distribution Channel Map-Market Size (USD Billion) & Growth Rate (%), 2023
• Figure 197.By Region Map-Market Size (USD Billion) & Growth Rate (%), 2023

Global chronic pain market is projected to witness a CAGR of 6.28% during the forecast period 2024-2031, growing from USD 85.82 billion in 2023 to USD 139.65 billion in 2031F.

Chronic pain market size is anticipated to increase under the influence of factors like the growing prevalence of chronic pain, the growing geriatric population, and ongoing clinical developments for pain management. Globally, the prevalence of chronic pain cases is on the rise due to multiple factors and is the main driver for market growth. The reasons such as the increasing aging population, growing cases of chronic diseases and pain-causing health conditions, growing cancer cases, and others are contributing to rising chronic pain prevalence, subsequently increasing the demand for chronic pain management solutions.

Additionally, the ongoing advancements and developments in clinical sciences for pain management are driving innovation in the market through new and advanced products. Nowadays, there are several classes of drugs like opioids, NSAIDs, antidepressants, local anesthetics, and many more for pain management, available in oral as well as topical dosage forms. Alongside, innovations in pain management devices for patients are encouraging market growth. Manufacturers are constantly competing for innovative product launches, clinical trials, patent filings, and utilizing market tactics for expansion of the market.

However, the major shortcoming for the market is its side effects, associated with pain management therapies, such as renal failure in long-term use of NSAIDs. Regulatory guidelines concerning the production and prescription of pain management drugs and devices are another major hurdle for market growth. The growing availability and popularity of alternative pain management techniques like acupuncture, chiropractic, physiotherapy, and others are posing significant challenges for the market. Despite this, the market is expected to grow at an exponential pace for the whole assessment period.

For instance, in March 2023, Nevro Corp announced the full market launch of its HFX iQ spinal cord stimulation (SCS) system in the United States. The launch follows the successful limited-market release of the product. HFX iQ uses HFX Algorithm which is built from over 20 million data points and 80,000 implanted patients to start patients on the program that is most likely to provide pain relief. The system combines clinical inputs, such as pain relief and pain score, with quality-of-life inputs, such as pain medication and activity level changes, to provide a personalized program setting for each patient.

Growing Prevalence of Chronic Pain

Chronic pain is one of the major clinical concerns around the world. Lower back pain, neck pain, and osteoarthritis are among the most common forms of chronic pain, accounting for a large percentage of disability worldwide. The major reasons for the growing prevalence of chronic pain include the aging population, sedentary lifestyle, obesity, injuries and trauma, cancer cases, and occupation-associated reasons. Conventional pain management techniques involve the use of opioids and several herbs while the modern method involves the use of nature-derived or synthetic chemicals and specialized devices to relieve the pain. Additionally, the growing corporate culture and obligation for long seating hours among the young generation is a leading cause of chronic pain and nutritional decline contributing more to this.

For instance, as per the news release of NIH published in May 2023, the rate of chronic pain among the population of the United States is 21% while the rate of high-impact chronic pain among adults is approximately 8%. Along with it, historical data suggests that the incidence of new cases of chronic pain was estimated to be 52.4 cases per 1,000 individuals per year.

Clinical Developments in Pain Management

The field of pain management has a wide range of approaches, including psychological interventions, pharmacology, invasive techniques, non-pharmacological approaches, and unconventional therapies. To establish evidence-based guidelines for pain management and ensure that safe and effective pain management therapies are available to all patients, including those experiencing health disparities, the NIH HEAL Initiative supports new clinical trials and the expansion of existing programs. Ongoing clinical trials for pain management are examining the outcomes and parameters of pharmaceutical development programs for pain medications. Comprehensive treatment of an individual's pain condition should include physical, emotional, and social aspects. The European Medicines Agency's scientific guideline guides the clinical development of new medicinal products for the treatment of pain. Market players are actively encouraging and adopting clinical developments to cater to the market needs.

In June 2023, Aspen Medical Products launched the Horizon PRO line of lower spine braces which are designed to eliminate the symptoms related to lower back pain caused due to muscle fatigue and spasms. The new line of Horizon PRO braces has several upgrades, including an improved version of Aspen's patented SlickTrack system that offers independent upper and lower compression, which is essential for optional symptom relief. Moreover, the new line features improved pull tabs to make the application of compression easier, breathable spacer material for added comfort, accessible panels for quicker customization, and improved indicators for proper patient sizing and comfort.

Dominance of the Drug Segment and Fast Growth for the Devices Segment

The drugs segment under the product type category in the chronic pain market is anticipated to dominate the market with a higher value share owing to the widespread use of drugs instead of devices for pain management. Pain management devices usually require medical assistance for usage while drugs can be administered without any assistance. Painkiller drugs of various classes like opioids, NSAIDs, analgesics, etc. are easily accessible and cost-efficient as compared to pain management devices. The adoption of pain management devices is increasing for chronic pain conditions to avoid the side effects of drugs, and it is anticipated to contribute to higher CAGR for the devices segment in the market.

For instance, in February 2023, Anglo-French Drugs & Industries Ltd. announced the launch of a new product called AFD-NP for the treatment of moderate to severe neuropathic pain. The product is a combination of two molecules, Nortriptyline 10 mg and Pregabalin 75 mg, and has been approved by the Drug Control Department. Compared to other products in the neuropathy segment that contain a combination of Nortriptyline and Gabapentin, AFD-NP is superior because it combines Nortriptyline with Pregabalin.

Neuropathic Pain to be the Leading Type of Pain Segment

Neuropathic pain is anticipated to be the leading type of pain segment among all types of pain experienced globally. It is a significant and growing issue, affecting approximately 6.9-10% of the global population according to recent data. Neuropathic pain arises from various causes, including damage to the peripheral or central nervous system, and is characterized by unique symptoms such as spontaneous pain, hypersensitivity, and sensory disturbances. Several products including drugs and devices have hit the market in recent times. Alongside, regulatory approvals for drugs used to manage neuropathic pain contribute greatly to market expansion.

For instance, in February 2024, OKYO Pharma received US FDA approval for its first investigational new drug for OK-101 in neuropathic corneal pain. OK-101 drug has received the first IND clearance from the FDA to begin clinical studies specifically for treating neuropathic corneal pain (NCP). NCP is a major unmet medical need and an Orphan disease listed in the National Organization for Rare Disorders. The initial trial of OK-101 to treat NCP will be a randomized, placebo-controlled, double-masked Phase 2 clinical trial and is planned to begin in the second quarter of 2024.

North America to be the Dominating Region

North America is anticipated to be the dominating region in the chronic pain market due to reasons like advancements in pain management methods and their increased adoption, a high aging population, and the increasing prevalence of chronic pain. The rising prevalence of chronic pain in North America is attributed to factors such as increasing cases of arthritis, bone and joint disorders, cancer, and other chronic conditions. Alongside it, the growing regulatory emphasis on the approval and development of innovative chronic pain management methods strengthens the lead of North America.

For instance, in May 2023, Abbott announced that its spinal cord stimulation (SCS) devices have received approval from the U.S. Food and Drug Administration (FDA) for the treatment of chronic back pain in individuals who have not undergone or are not eligible for back surgery, also known as non-surgical back pain. The labeling expansion was backed by results from the DISTINCT study, which revealed that Abbott's proprietary BurstDR SCS technology improved pain levels, daily activity performance, and emotional well-being in people suffering from chronic back pain.

Future Market Scenario

With growing digital health technologies, such as smartphones and wearables, understanding individuals' pain experiences and identifying patterns and triggers in real time has significantly impacted chronic pain management techniques. Patient-specific data helps in monitoring periods of high pain flare risk, identifying individual and contextual triggers, and optimizing treatment delivery, engagement, and effectiveness.

Similar to other fields, using artificial intelligence for cognitive pain therapy intervention could be an essential step in providing effective patient-centered care. For instance, in August 2023, Two Canadian senior care facilities introduced PainChek, an AI-based technology that assesses pain in residents, making them the first long-term care facilities in North America to adopt such a solution. PainChek is the world's first regulatory-cleared medical device designed to detect and quantify pain in real time by analyzing micro facial expressions indicative of pain.

Key Players Landscape and Outlook

Eli Lilly and Company, Becton, Dickinson and Company, Medtronic plc, Johnson & Johnson Pte. Ltd., Novartis AG, AstraZeneca PLC, Bristol-Myers Squibb Company, Sanofi S.A., Pfizer Inc., GlaxoSmithKline plc. are some of the leading players in the chronic pain market with years of experience and trust. These firms are well-established and have extensive product offerings. There are a lot of small players and generic drug manufacturers as well in the market. Extensive product pipelines and R&D activities by these companies support the growth of the market in the upcoming future.

In November 2023, BehaVR and Fern Health signed an agreement to merge their businesses and create a new digital care management solution for chronic pain. The new offering, which will be branded as RealizedCare, aims to meet the rising demand for evidence-based, scalable, and economically viable solutions for a range of mental and behavioral health burdens, starting with chronic pain.

Table of Contents

1.Research Methodology

2.Project Scope & Definitions

3.Executive Summary

4.Global Chronic Pain Market Outlook, 2017-2031F

• 4.1.Market Size & Forecast
  • 4.1.1. By Value
  • 4.1.2. By Volume
• 4.2.By Product
  • 4.2.1.Drugs
    • 4.2.1.1.Opioids
    • 4.2.1.2.Non-steroidal Anti-inflammatory Drugs (NSAIDs)
    • 4.2.1.3.Anesthetics
    • 4.2.1.4.Anticonvulsants
    • 4.2.1.5.Anti-depressants
    • 4.2.1.6.Other Non-narcotic Analgesics
  • 4.2.2.Devices
    • 4.2.2.1.Neurostimulation Devices
    • 4.2.2.2.Brain and Spinal Cord Stimulation (SCS) Devices
    • 4.2.2.3.Analgesics Infusion Pumps
• 4.3.By Type of Pain
  • 4.3.1.Neuropathic Pain
  • 4.3.2.Arthritis Pain
  • 4.3.3.Chronic Back Pain
  • 4.3.4.Cancer Pain
  • 4.3.5.Migraine
  • 4.3.6.Fibromyalgia
  • 4.3.7.Others
• 4.4.By Indication
  • 4.4.1.Musculoskeletal
  • 4.4.2.Neuropathy
  • 4.4.3.Oncology
  • 4.4.4.Others
• 4.5.By Distribution Channel
  • 4.5.1.Hospital Pharmacies
  • 4.5.2.Retail Pharmacies
  • 4.5.3.Online Pharmacies
• 4.6.By Region
  • 4.6.1.North America
  • 4.6.2.Europe
  • 4.6.3.Asia-Pacific
  • 4.6.4.South America
  • 4.6.5.Middle East and Africa
• 4.7.By Company Market Share (%), 2023

5.Global Chronic Pain Market Outlook, By Region, 2017-2031F

• 5.1.North America*
  • 5.1.1.Market Size & Forecast
    • 5.1.1.1.By Value
    • 5.1.1.2.By Volume
  • 5.1.2.By Product
    • 5.1.2.1.Drugs
    • 5.1.2.1.1.Opioids
    • 5.1.2.1.2.Non-steroidal Anti-inflammatory Drugs (NSAIDs)
    • 5.1.2.1.3.Anesthetics
    • 5.1.2.1.4.Anticonvulsants
    • 5.1.2.1.5.Anti-depressants
    • 5.1.2.1.6.Other Non-narcotic Analgesics
    • 5.1.2.2.Devices
    • 5.1.2.2.1.Neurostimulation Devices
    • 5.1.2.2.2.Brain and Spinal Cord Stimulation (SCS) Devices
    • 5.1.2.2.3.Analgesics Infusion Pumps
  • 5.1.3.By Type of Pain
    • 5.1.3.1.Neuropathic Pain
    • 5.1.3.2.Arthritis Pain
    • 5.1.3.3.Chronic Back Pain
    • 5.1.3.4.Cancer Pain
    • 5.1.3.5.Migraine
    • 5.1.3.6.Fibromyalgia
    • 5.1.3.7.Others
  • 5.1.4.By Indication
    • 5.1.4.1.Musculoskeletal
    • 5.1.4.2.Neuropathy
    • 5.1.4.3.Oncology
    • 5.1.4.4.Others
  • 5.1.5.By Distribution Channel
    • 5.1.5.1.Hospital Pharmacies
    • 5.1.5.2.Retail Pharmacies
    • 5.1.5.3.Online Pharmacies
  • 5.1.6.United States*
    • 5.1.6.1.Market Size & Forecast
    • 5.1.6.1.1.By Value
    • 5.1.6.1.2.By Volume
    • 5.1.6.2.By Product
    • 5.1.6.2.1.Drugs
    • 5.1.6.2.1.1.Opioids
    • 5.1.6.2.1.2.Non-steroidal Anti-inflammatory Drugs (NSAIDs)
    • 5.1.6.2.1.3.Anesthetics
    • 5.1.6.2.1.4.Anticonvulsants
    • 5.1.6.2.1.5.Anti-depressants
    • 5.1.6.2.1.6.Other Non-narcotic Analgesics
    • 5.1.6.2.2.Devices
    • 5.1.6.2.2.1.Neurostimulation Devices
    • 5.1.6.2.2.2.Brain and Spinal Cord Stimulation (SCS) Devices
    • 5.1.6.2.2.3.Analgesics Infusion Pumps
    • 5.1.6.3.By Type of Pain
    • 5.1.6.3.1.Neuropathic Pain
    • 5.1.6.3.2.Arthritis Pain
    • 5.1.6.3.3.Chronic Back Pain
    • 5.1.6.3.4.Cancer Pain
    • 5.1.6.3.5.Migraine
    • 5.1.6.3.6.Fibromyalgia
    • 5.1.6.3.7.Others
    • 5.1.6.4.By Indication
    • 5.1.6.4.1.Musculoskeletal
    • 5.1.6.4.2.Neuropathy
    • 5.1.6.4.3.Oncology
    • 5.1.6.4.4.Others
    • 5.1.6.5.By Distribution Channel
    • 5.1.6.5.1.Hospital Pharmacies
    • 5.1.6.5.2.Retail Pharmacies
    • 5.1.6.5.3.Online Pharmacies
  • 5.1.7.Canada
  • 5.1.8.Mexico

All segments will be provided for all regions and countries covered

• 5.2.Europe
  • 5.2.1.Germany
  • 5.2.2.France
  • 5.2.3.Italy
  • 5.2.4.United Kingdom
  • 5.2.5.Russia
  • 5.2.6.Netherlands
  • 5.2.7.Spain
  • 5.2.8.Turkey
  • 5.2.9.Poland
• 5.3.Asia-Pacific
  • 5.3.1.India
  • 5.3.2.China
  • 5.3.3.Japan
  • 5.3.4.Australia
  • 5.3.5.Vietnam
  • 5.3.6.South Korea
  • 5.3.7.Indonesia
  • 5.3.8.Philippines
• 5.4.South America
  • 5.4.1.Brazil
  • 5.4.2.Argentina
• 5.5.Middle East & Africa
  • 5.5.1.Saudi Arabia
  • 5.5.2.UAE
  • 5.5.3.South Africa

6.Market Mapping, 2023

• 6.1.By Product
• 6.2.By Type of Pain
• 6.3.By Indication
• 6.4.By Distribution Channel
• 6.5.By Region

7.Macro Environment and Industry Structure

• 7.1.Demand Supply Analysis
• 7.2.Import Export Analysis
• 7.3.Value Chain Analysis
• 7.4.PESTEL Analysis
  • 7.4.1.Political Factors
  • 7.4.2.Economic System
  • 7.4.3.Social Implications
  • 7.4.4.Technological Advancements
  • 7.4.5.Environmental Impacts
  • 7.4.6.Legal Compliances and Regulatory Policies (Statutory Bodies Included)
• 7.5.Porter's Five Forces Analysis
  • 7.4.7.Supplier Power
  • 7.4.8.Buyer Power
  • 7.4.9.Substitution Threat
  • 7.4.10.Threat from New Entrant
  • 7.4.11.Competitive Rivalry

8.Market Dynamics

• 8.1.Growth Drivers
• 8.2.Growth Inhibitors (Challenges and Restraints)

9.Regulatory Framework and Innovation

• 9.1.Clinical Trials
• 9.2.Patent Landscape
• 9.3.Regulatory Approvals
• 9.4.Innovations/Emerging Technologies

10.Key Players Landscape

• 10.1.Competition Matrix of Top Five Market Leaders
• 10.2.Market Revenue Analysis of Top Five Market Leaders (in %, 2023)
• 10.3.Mergers and Acquisitions/Joint Ventures (If Applicable)
• 10.4.SWOT Analysis (For Five Market Players)

11.Pricing Analysis

12.Case Studies

13.Key Players Outlook

• 13.1.Becton, Dickinson and Company
  • 13.1.1.Company Details
  • 13.1.2.Key Management Personnel
  • 13.1.3.Products & Services
  • 13.1.4.Financials (As reported)
  • 13.1.5.Key Market Focus & Geographical Presence
  • 13.1.6.Recent Developments
• 13.2.Eli Lilly and Company
• 13.3.Medtronic plc
• 13.4.Johnson & Johnson Pte. Ltd.
• 13.5.Novartis AG
• 13.6.AstraZeneca PLC
• 13.7.Bristol-Myers Squibb Company
• 13.8.Sanofi S.A.
• 13.9.Pfizer Inc.
• 13.10.GlaxoSmithKline plc.

Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.

14.Strategic Recommendations

15.About Us & Disclaimer